Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model
Authors:
- Kunie AndoKAKunie Ando
- Andreea-Claudia KosaAKAndreea-Claudia Kosa
- Yasmina MehadjiYMYasmina Mehadji
- Hinde LasriHLHinde Lasri
- Lidia Lopez-GutierrezLidia Lopez-Gutierrez
- Carolina Quintanilla-SánchezCQCarolina Quintanilla-Sánchez
- Emmanuel AydinEAEmmanuel Aydin
- Emilie DoeraeneEmilie Doeraene
- Alain Wathelet-DepauwAWAlain Wathelet-Depauw
- Siranjeevi NagarajSNSiranjeevi Nagaraj
- Jean-Pierre BrionJBJean-Pierre Brion
- Karelle LeroyKLKarelle Leroy
Open Access
- 21 January 2025
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 159
Abstract
Alzheimer’s disease is characterized by two key neuropathological lesions: amyloid plaques composed of amyloid β and neurofibrillary tangles formed by hyperphosphorylated tau. Amyloid β is produced through successive cleavages of amyloid precursor protein (APP) via the amyloidogenic pathway. While increasing evidence suggests that APP plays critical roles in neuronal function and that its proteolytic derivative, sAPPα, has neurotrophic effects, the impact of APP deletion on both amyloid and tau pathologies remains poorly understood. Here, we introduce a novel transgenic mouse model, 5xFAD×Tg30XAPP-/-, in which murine APP is deleted in the presence of both amyloid and tau pathologies. Using this innovative model, we demonstrate for the first time that deletion of APP exacerbates tau aggregation, amyloid deposition, and gliosis compared to control 5xFAD×Tg30 mice. This study provides the first in vivo evidence that APP deletion has profound and detrimental effects on both amyloid and tau pathologies in a transgenic model of Alzheimer’s disease, highlighting the previously unappreciated role of APP in the regulation of these neurodegenerative processes.Keywords
Funding Information
- Belgian FNRS (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
- Belgian Fonds de la Recherche Scientifique Médicale (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
- Fund Aline (King Baudoin Foundation (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
- Belgian Fondation Recherche Alzheimer/Stichting Alzheimer Onderzoek (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
- ULB Génicot Fund (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
- Fondation Médicale Reine Elisabeth (T.0023.15, 14001, 2021/0028, 2019/0027, 2018/0021)
This publication has 53 references indexed in Scilit:
- Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer’s disease pathology progressionActa Neuropathologica, 2024
- Physiological Roles of β-amyloid in Regulating Synaptic Function: Implications for AD PathophysiologyNeuroscience Bulletin, 2022
- Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivoActa Neuropathologica, 2019
- Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse modelActa Neuropathologica, 2015
- Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer’s brainsActa Neuropathologica, 2013
- α-Secretase ADAM10 as Well as αAPPs Is Reduced in Platelets and CSF of Alzheimer Disease PatientsMolecular Medicine, 2002
- Cerebrospinal Fluid Levels of -Secretase--Cleaved Soluble Amyloid Precursor Protein Mirror Cognition in a Swedish Family With Alzheimer Disease and a Gene MutationArchives of Neurology, 1997
- Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tauJournal of Neuroscience Research, 1997
- β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activityCell, 1995
- Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404Journal of Neuroscience Research, 1994